Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

Swedish Medical Center

Status and phase: Terminated; Phase 2

Conditions: Small Cell Lung Cancer

Treatments: Drug: Oxaliplatin (Eloxatin); Drug: Irinotecan (CPT-11)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00316433

OX-03-099

Details and patient eligibility

About

The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previously untreated extensive small cell lung cancer
• No prior chemotherapy
• No prior radiotherapy except for the treatment of brain metastases

Exclusion criteria

• Prior treatment for extensive stage small cell lung cancer
• Known hypersensitivity to any of the components of oxaliplatin or CPT-11
• Greater than grade 2 peripheral neuropathy
• Known HIV or Hepatitis B or C (active, previously treated or both)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)